Matrix Metalloproteinase-7 and Osteopontin Serum Levels as Biomarkers for Biliary Atresia.
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
01 07 2023
01 07 2023
Historique:
medline:
19
6
2023
pubmed:
16
6
2023
entrez:
16
6
2023
Statut:
ppublish
Résumé
Matrix metallopeptidase-7 (MMP-7) and osteopontin (OPN) are important components in the pathophysiology of fibrosis in biliary atresia (BA). There has been much recent interest in MMP-7 serum level in the diagnosis of BA. We aimed to assess the diagnostic accuracy and prognostic value of both MMP-7 and OPN in a Western BA study. Diagnostic value was assessed by comparison of serum MMP-7 and OPN levels in infants with BA and age-matched cholestatic controls. Prognostic value was assessed through subsequent clearance of jaundice (COJ) and need for liver transplantation (LT). Serum was assessed from 32 BA and 27 controls. Median MMP-7 was higher in BA (96.4 vs 35 ng/mL; P < 0.0001) with an optimal cut-off value of 69 ng/mL. Sensitivity and specificity was 68% and 93%, respectively [negative predictive value (NPV) = 71%]. Similarly, median OPN was higher in BA (1952 vs 1457 ng/mL; P = 0.0001) and an optimal cut-off of 1611 ng/mL. Sensitivity and specificity was 84% and 78%, respectively (NPV = 81%). MMP-7 level correlated positively with Ishak liver fibrosis score (r = 0.27, P = 0.04). Neither MMP-7 (70 vs 100 ng/mL; P = 0.2) nor OPN (1969 vs 1939 ng/mL; P = 0.3) were predictive of COJ, or need for LT (99 vs 79 ng/mL; P = 0.7, and 1981 vs 1899 ng/mL; P = 0.2), respectively. MMP-7 and OPN may have contributory value in the diagnosis of BA, but remain far of the "gold standard" role. Much more prospective data are required and collaborative multi-center initiatives should be the next logical steps.
Identifiants
pubmed: 37326848
doi: 10.1097/MPG.0000000000003792
pii: 00005176-202307000-00015
doi:
Substances chimiques
Osteopontin
106441-73-0
Matrix Metalloproteinase 7
EC 3.4.24.23
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
97-102Informations de copyright
Copyright © 2023 by European Society for European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Hartley JL, Davenport M, Kelly DA. Biliary atresia. Lancet. 2009;374:1704–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19914515 .
Davenport M. Biliary atresia: clinical aspects. Semin Pediatr Surg. 2012;21:175–84.
Feldman AG, Sokol RJ. Recent developments in diagnostics and treatment of neonatal cholestasis. Semin Pediatr Surg. 2020;29:150945.
Lertudomphonwanit C, Mourya R, Fei L, et al. Large-scale proteomics identifies MMP-7 as a sentinel of epithelial injury and of biliary atresia. Sci Transl Med. 2017;9:1–12.
Yang L, Zhou Y, Xu P, et al. Diagnostic accuracy of serum matrix metalloproteinase-7 for biliary atresia. Hepatology. 2018;68:2069–77.
Wu JF, Jeng YM, Chen HL, Ni YH, Hsu HY, Chang MH. Quantification of serum matrix metallopeptide 7 levels may assist in the diagnosis and predict the outcome for patients with biliary atresia. J Pediatr. 2019;208:30–37.e1. doi:10.1016/j.jpeds.2018.12.006.
doi: 10.1016/j.jpeds.2018.12.006
Jiang J, Wang J, Shen Z, et al. Serum MMP-7 in the diagnosis of biliary atresia. Pediatrics. 2019;144(5):e20190902. doi:10.1542/peds.2019-0902.
doi: 10.1542/peds.2019-0902
Rohani P, Mirrahimi SB, Bashirirad H, et al. Serum matrix metalloproteinase-7 levels in infants with cholestasis and biliary atresia. BMC Pediatr. 2022;22:1–10. doi:10.1186/s12887-022-03409-9.
doi: 10.1186/s12887-022-03409-9
Sakaguchi H, Konishi K-I, Yasuda R, et al. Serum matrix metalloproteinase-7 in biliary atresia: a Japanese multicenter study. Hepatol Res. 2022;52:479–87.
Singh TR, Goel P, Bajpai M, et al. Serum matrix metalloproteinase 7 as a diagnostic and prognostic biomarker for extrahepatic biliary atresia. J Indian Assoc Pediatr Surg. 2022;27(2):227–35. doi:10.4103/jiaps.JIAPS_389_20.
doi: 10.4103/jiaps.JIAPS_389_20
Wu B, Zhou Y, Tian X, Cai W, Xiao Y. Diagnostic values of plasma matrix metalloproteinase-7, interleukin-8, and gamma-glutamyl transferase in biliary atresia. Eur J Pediatr. 2022;181:3945–53. doi:10.1007/s00431-022-04612-7.
doi: 10.1007/s00431-022-04612-7
Chi S, Xu P, Yu P, et al. Dynamic analysis of serum MMP-7 and its relationship with disease progression in biliary atresia: a multicenter prospective study. Hepatol Int. 2022;16:954–63.
Karbasian F, Mashhadiagha A, Anbardar MH, et al. Questioning diagnostic value of serum matrix metalloproteinase 7 for biliary atresia. J Clin Exp Hepatol. 2023;13:265–72.
He L, Ip DKM, Tam G, Lui VCH, Tam PKH, Chung PHY. Biomarkers for the diagnosis and post-Kasai portoenterostomy prognosis of biliary atresia: a systematic review and meta-analysis. Sci Rep. 2021;11:1–14. doi:10.1038/s41598-021-91072-y.
doi: 10.1038/s41598-021-91072-y
Irvine KM, Okano S, Patel PJ, et al. Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep. 2021;11:2858.
Lam S, Singh R, Dillman JR, et al. Serum matrix metalloproteinase 7 is a diagnostic biomarker of biliary injury and fibrosis in pediatric autoimmune liver disease. Hepatol Commun. 2020;4:1680–93.
Irvine KM, Wockner LF, Hoffmann I, et al. Multiplex serum protein analysis identifies novel biomarkers of advanced fibrosis in patients with chronic liver disease with the potential to improve diagnostic accuracy of established biomarkers. PLoS One. 2016;11:e0167001.
Whitington PF, Malladi P, Melin-Aldana H, Azzam R, Mack CL, Sahai A. Expression of osteopontin correlates with portal biliary proliferation and fibrosis in biliary atresia. Pediatr Res. 2005;57:837–44.
Honsawek S, Chayanupatkul M, Chongsrisawat V, Vejchapipat P, Poovorawan Y. Increased osteopontin and liver stiffness measurement by transient elastography in biliary atresia. World J Gastroenterol. 2010;16:5467–73.
Kerola A, Lampela H, Lohi J, et al. Increased MMP-7 expression in biliary epithelium and serum underpins native liver fibrosis after successful portoenterostomy in biliary atresia. J Pathol Clin Res. 2016;2:187–98.
Ke B, Fan C, Yang L, Fang X. Matrix metalloproteinases-7 and kidney fibrosis. Front Physiol. 2017;8:21.
Zhou D, Tian Y, Sun L, et al. Matrix metalloproteinase-7 is a urinary biomarker and pathogenic mediator of kidney fibrosis. J Am Soc Nephrol. 2017;28:598–611.
Gharib SA, Altemeier WA, Van Winkle LS, et al. Matrix metalloproteinase-7 coordinates airway epithelial injury response and differentiation of ciliated cells. Am J Respir Cell Mol Biol. 2013;48:390–6.
Pardo A, Cabrera S, Maldonado M, Selman M. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Respir Res. 2016;17:23.
Mohammadi A, Balan I, Yadav S, et al. Post-COVID-19 pulmonary fibrosis. Cureus. 2022;14:e22770.
Jakubowska K, Pryczynicz A, Iwanowicz P, et al. Expressions of matrix metalloproteinases (MMP-2, MMP-7, and MMP-9) and their inhibitors (TIMP-1, TIMP-2) in inflammatory bowel diseases. Gastroenterol Res Pract. 2016;2016:2456179.
Lakshminarayanan B, Davenport M. Biliary atresia: a comprehensive review. J Autoimmun. 2016;73:1–9.
Chung PHY, Zheng S, Tam PKH. Biliary atresia: east versus west. Semin Pediatr Surg. 2020;29:150950.
Davenport M, Muntean A, Hadzic N. Biliary atresia: clinical phenotypes and aetiological heterogeneity. J Clin Med. 2021;10(23):5675. doi:10.3390/jcm10235675.
doi: 10.3390/jcm10235675
Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–9.
Goksuluk D, Korkmaz S, Zararsiz GKA. easyROC: an interactive web-tool for ROC curve analysis using R language environment. R J. 2016;8:213–30.
Lindsey ML, Escobar GP, Mukherjee R, et al. Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation. 2006;113:2919–28.
Szklarczyk A, Conant K, Owens DF, Ravin R, McKay RD, Gerfen C. Matrix metalloproteinase-7 modulates synaptic vesicle recycling and induces atrophy of neuronal synapses. Neuroscience. 2007;149:87–98.
Zeng Z-S, Shu W-P, Cohen AM, Guillem JG. Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases. Clin Cancer Res. 2002;8:144–8.
Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure. Adv Drug Deliv Rev. 2016;97:4–27.
Cui N, Hu M, Khalil RA. Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci. 2017;147:1–73.
Szklarczyk A, Oyler G, McKay R, Gerfen C, Conant K. Cleavage of neuronal synaptosomal-associated protein of 25 kDa by exogenous matrix metalloproteinase-7. J Neurochem. 2007;102:1256–63.
Huang C-C, Chuang J-H, Chou M-H, et al. Matrilysin (MMP-7) is a major matrix metalloproteinase upregulated in biliary atresia-associated liver fibrosis. Mod Pathol. 2005;18:941–50.
Asai A, Miethke A, Bezerra JA. Pathogenesis of biliary atresia: defining biology to understand clinical phenotypes. Nat Rev Gastroenterol Hepatol. 2015;12:342–52.
Russi AE, Bezerra JA. A single-cell view of biliary atresia. Nat Rev Gastroenterol Hepatol. 2021;18:219–20.
Wang J, Xu Y, Chen Z, et al. Liver immune profiling reveals pathogenesis and therapeutics for biliary atresia. Cell. 2020;183:1867–1883.e26.
Nomden M, Beljaars L, Verkade HJ, Hulscher JBF, Olinga P. Current concepts of biliary atresia and matrix metalloproteinase-7: a review of literature. Front Med (Lausanne). 2020;7:1–16.
Kazanecki CC, Uzwiak DJ, Denhardt DT. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem. 2007;102:912–24.
Song Z, Chen W, Athavale D, et al. Osteopontin takes center stage in chronic liver disease. Hepatology. 2021;73:1594–608.
Bezerra JA, Tiao G, Ryckman FC, et al. Genetic induction of proinflammatory immunity in children with biliary atresia. Lancet. 2002;360:1653–9.
Huang L, Wei M-F, Feng J-X. Abnormal activation of OPN inflammation pathway in livers of children with biliary atresia and relationship to hepatic fibrosis. Eur J Pediatr Surg. 2008;18:224–9.
Xu C, Wu Y, Liu N. Osteopontin in autoimmune disorders: current knowledge and future perspective. Inflammopharmacology. 2022;30:385–96.
Evans HM, Asher MI, Cameron-Christie S, et al. Ethnic disparity in the incidence and outcome of biliary atresia in New Zealand. J Pediatr Gastroenterol Nutr. 2018;66:218–21.
Luo Z, Shivakumar P, Mourya R, Gutta S, Bezerra JA. Gene expression signatures associated with survival times of pediatric patients with biliary atresia identify potential therapeutic agents. Gastroenterology. 2019;157:1138–52.e14.